Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Escape from T-cell–targeting immunotherapies in acute myeloid leukemia

Jayakumar Vadakekolathu, Sergio Rutella

Blood (2024) 143 (26): 2689–2700.

https://doi.org/10.1182/blood.2023019961

Published: 2024

Journal Articles

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2023-184741

Published: 2023

Journal Articles

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Amanda F Cashen, Nitin Mahajan, Yanira Ruiz-Heredia, Alejandro Martín-Muñoz, Santiago Barrio, Melissa M Berrien-Elliott, Jan Davidson-Moncada, Todd A Fehniger

Blood (2023) 142 (Supplement 1): 4813.

https://doi.org/10.1182/blood-2023-184986

Published: 2023

Journal Articles

Spatially Resolved Transcriptomics Unveils Unique T-Cell Dysfunctional States and Prognostic Gene Expression Signatures in TP53 -Mutated Acute Myeloid Leukemia

Jayakumar Vadakekolathu, Heidi Altmann, Manja Wobus, Malte von Bonin, Marc Schmitz, Gustavo B. Baretton, Robert Zeiser, Martin Bornhäuser, Sergio Rutella

Blood (2023) 142 (Supplement 1): 291.

https://doi.org/10.1182/blood-2023-174871

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 466.

https://doi.org/10.1182/blood-2023-184923

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Nupur Bhatnagar, Vincent Petit, Jayakumar Vadakekolathu, Christian Pinset, Nitin Mahajan, John Dean, Christine Spingola, Laura Arthur, David Boocock, Clare Coveney, John Muth, Jan Baughman, Melissa M Berrien-Elliott, Marc Sitbon, Matthew L. Cooper, Jan Davidson-Moncada, Todd A Fehniger, Sergio Rutella

Blood (2023) 142 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2023-178868

Published: 2023

Journal Articles

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 7400–7401.

https://doi.org/10.1182/blood-2022-157199

Published: 2022

Journal Articles

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung On Yau, Rupkatha Mukhopadhyay, Heidi Altmann, Michael Kramer, Hanna A. Knaus, Joshua F. Zeidner, Vedran Radojcic, Andrea Arruda, Mark D. Minden, Sarah K Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik

Blood (2021) 138 (Supplement 1): 223.

https://doi.org/10.1182/blood-2021-145854

Published: 2021

Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood (2021) 137 (6): 751–762.

https://doi.org/10.1182/blood.2020007732

Published: 2021

Includes: Supplemental data

Journal Articles

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Sarah E. Church, PhD, Michael P. Rettig, PhD, Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Farhad Ravandi, MBBS, Antonio Curti, MDPhD, Max S. Topp, MD, John Muth, MS, Patrick Kaminker, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Leo Luznik, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134921

Published: 2020

Journal Articles

A Three-Gene Immune Signature Including IDO1 , BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

Simone Ragaini, MD, Sarah Wagner, BSc MSc, Giovanni Marconi, MD, Sarah Parisi, MDPhD, Chiara Sartor, MD, Jacopo Nanni, MD, Gianluca Cristiano, MD, Annalisa Talami, MD, Matteo Olivi, MD, Darina Ocadlikova, PhD, Marilena Ciciarello, PhD, Giulia Corradi, PhD, Emanuela Ottaviani, Cristina Papayannidis, MDPhD, Stefania Paolini, MD PhD, Jayakumar Vadakekolathu, PhD, Michele Cavo, Sergio Rutella, MDPhDFRCPath, Antonio Curti, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139665

Published: 2020

Journal Articles

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-136919

Published: 2020

Journal Articles

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Heidi Altmann, PhD, Sarah E. Church, PhD, Hanna A Knaus, MD, Mark D. Minden, Jan K Davidson-Moncada, MDPhD, Sarah K Tasian, MD, Martin Bornhäuser, MD, Ivana Gojo, MD, Leo Luznik, MD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134779

Published: 2020

Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 733.

https://doi.org/10.1182/blood-2019-122073

Published: 2019

Journal Articles

Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment

Marilena Ciciarello, PhD, Giulia Corradi, PhD, Sabina Sangaletti, PhD, Barbara Bassani, Giorgia Simonetti, PhD, Jayakumar Vadakekolathu, PhD, Giovanni Marconi, Giovanni Martinelli, MD, Mario Paolo Colombo, Sergio Rutella, MDPhDFRCPath, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 1212.

https://doi.org/10.1182/blood-2019-126512

Published: 2019

Journal Articles

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Stephen Reeder, BSc, Clare Coveney, PhD, Sergio Rutella, MDPhDFRCPath

Blood (2019) 134 (Supplement_1): 2726.

https://doi.org/10.1182/blood-2019-124717

Published: 2019

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

An IDO1 -Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia

Simone Ragaini, MD, Sarah Wagner, BSc MSc, Giovanni Marconi, Sarah Parisi, MD PhD, Chiara Sartor, MD, Jacopo Nanni, MD, Gianluca Cristiano, Annalisa Talami, MD, Matteo Olivi, MD, Darina Ocadlikova, PhD, Marilena Ciciarello, PhD, Giulia Corradi, PhD, Emanuela Ottaviani, Cristina Papayannidis, Stefania Paolini, MD PhD, Jayakumar Vadakekolathu, PhD, Michele Cavo, Sergio Rutella, MD PhD FRCPath, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 5193.

https://doi.org/10.1182/blood-2019-128348

Published: 2019

Journal Articles

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Sergio Rutella, MD PhD FRCPath, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Elena Viboch, MSc, Amy H Sullivan, BSc, Tressa Hood, MSc, Sarah E. Warren, PhD, Alessandra Cesano, MD PhD, Ross La Motte-Mohs, PhD, John Muth, MS, Helene Lelièvre, PhD PharmD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MD PhD

Blood (2018) 132 (Supplement 1): 444.

https://doi.org/10.1182/blood-2018-99-111539

Published: 2018

Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 764.

https://doi.org/10.1182/blood-2018-99-117085

Published: 2018

NARROW

Escape from T-cell–targeting immunotherapies in acute myeloid leukemia

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Spatially Resolved Transcriptomics Unveils Unique T-Cell Dysfunctional States and Prognostic Gene Expression Signatures in TP53 -Mutated Acute Myeloid Leukemia

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

A Three-Gene Immune Signature Including IDO1 , BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

An IDO1 -Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only